Welcome to vnonline.co.uk

vnonline.co.uk provides the veterinary nursing profession with the latest news and industry developments, as well as events, resources, learning materials and careers.

Our website is dedicated to veterinary nurses and we strive to provide a platform where you can voice and explore your interests.

Not a member yet? Sign up for free!

Register for free with vnonline.co.uk to gain unlimited access to news, resources, jobs and much more!



Click here to become a member






Log in to vnonline

Forgot your password?

Posted: 18th December 2017

Guidance for monoclonal antibody use in animals approved
Monoclonal antibodies are immune proteins that recognise and bind to a specific target protein.
Approval follows review of relevant scientific evidence

The first ever guidance for monoclonal antibody use in animals has been approved by the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use (CVMP).

The guidance, prepared by CVMP’s Ad Hoc Expert Group on Veterinary Novel Therapies, takes the form of a question-and-answer document.  It relates to the quality control for potential contaminants, stability testing, reproductive safety studies and data to address the potential for indirect adverse effects.

Monoclonal antibodies are immune proteins that recognise and bind to a specific target protein. Until recently they have not been used in veterinary medicine. In humans, however, they have been authorised for many years against cancer and diseases affecting the immune system.

Due to a lack of regulatory guidance, therapies that are new to veterinary medicine face particular challenges. But in February 2017, the first veterinary medicine containing a monoclonal antibody was recommended for approval by the CVMP.

Veterinary novel therapies refer to therapies that are either new, or new only to the veterinary sphere, but well known in the context of human medicine.

Interest and research into veterinary novel therapies have increased in recent years. Following a review of relevant scientific evidence, the CVMP identified monoclonal antibodies as one of the priority areas that would benefit from specific guidance.




Become a member or log in to add this story to your CPD history



Latest news | Careers | Events | Resources | Contact us | Terms and conditions | Data Protection and Privacy |Cookie policy | About us | Copyright
© 2024 Vision Media, all rights reserved. vnonline.co.uk is not responsible for the content of external websites.